| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c18ba6b5a2e42fbc7fc3017f50a6bb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9019c0ce5cb7b82c85e121f6cac86dce |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate |
2010-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f5e4f8457f743fb737ea7f708b02810
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa70a2aa6b6370a099d82a7dc68b6c01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf92a941410e161a362df1ebf5da0e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b02bef8228d68f8ae388e80a8e562f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff025f5c2f63960d6ab1d5b5a4519166 |
| publicationDate |
2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-102369281-B |
| titleOfInvention |
HLA-A24-binding cancer antigen peptide derived from SOX2 |
| abstract |
Disclosed are: a peptide capable of inducing a cytotoxic T cell that targets cancer cells, wherein the peptide comprises an amino acid sequence derived from a polypeptide encoded by Sox2 gene or an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in the aforementioned amino acid sequence and can be presented as an antigen in conjunction with HLA-A24; a CTL induced by the peptide; a pharmaceutical composition containing the peptide and/or the CTL; and use of the peptide for the induction of a CTL. |
| priorityDate |
2009-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |